BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10734643)

  • 1. [General rules for the study of pancreatic cancer by molecular biological aspect].
    Omata M; Tada M
    Nihon Geka Gakkai Zasshi; 2000 Feb; 101(2):233-6. PubMed ID: 10734643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetics of pancreatic cancer: recent advances in molecular diagnosis].
    Hayashi N; Egami H; Ogawa M
    Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):476-81. PubMed ID: 12094699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
    Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
    Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular diagnosis of pancreatic cancer.
    Inoue S; Tezel E; Nakao A
    Hepatogastroenterology; 2001; 48(40):933-8. PubMed ID: 11490843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar et al., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res., 7: 4115-4121, 2001.
    Liu F
    Clin Cancer Res; 2001 Dec; 7(12):3853-6. PubMed ID: 11751474
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions.
    Parwani AV; Geradts J; Caspers E; Offerhaus GJ; Yeo CJ; Cameron JL; Klimstra DS; Maitra A; Hruban RH; Argani P
    Mod Pathol; 2003 Apr; 16(4):299-308. PubMed ID: 12692194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-suppressive pathways in pancreatic carcinoma.
    Rozenblum E; Schutte M; Goggins M; Hahn SA; Panzer S; Zahurak M; Goodman SN; Sohn TA; Hruban RH; Yeo CJ; Kern SE
    Cancer Res; 1997 May; 57(9):1731-4. PubMed ID: 9135016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis.
    van Heek T; Rader AE; Offerhaus GJ; McCarthy DM; Goggins M; Hruban RH; Wilentz RE
    Am J Clin Pathol; 2002 May; 117(5):755-65. PubMed ID: 12090425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
    Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
    Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer.
    Salek C; Minarikova P; Benesova L; Nosek V; Strnad R; Zavoral M; Minarik M
    Anticancer Res; 2009 May; 29(5):1803-10. PubMed ID: 19443408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New molecular targets in pancreatic cancer].
    Torrisani J; Bournet B; Cordelier P; Buscail L
    Bull Cancer; 2008 May; 95(5):503-12. PubMed ID: 18541514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic diagnosis of pancreatic cancer.
    Mizumoto K; Tanaka M
    J Hepatobiliary Pancreat Surg; 2002; 9(1):39-44. PubMed ID: 12021896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
    Loukopoulos P; Kanetaka K; Takamura M; Shibata T; Sakamoto M; Hirohashi S
    Pancreas; 2004 Oct; 29(3):193-203. PubMed ID: 15367885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
    de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of DPC4/Smad4, p21wafI, and p16 in human pancreatic cancer].
    Gu LJ; Chen J; Lu ZH; Li L; Zhou WX; Luo YF
    Ai Zheng; 2002 Feb; 21(2):132-7. PubMed ID: 12479060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
    Moore PS; Sipos B; Orlandini S; Sorio C; Real FX; Lemoine NR; Gress T; Bassi C; Klöppel G; Kalthoff H; Ungefroren H; Löhr M; Scarpa A
    Virchows Arch; 2001 Dec; 439(6):798-802. PubMed ID: 11787853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.
    Moskaluk CA; Hruban RH; Kern SE
    Cancer Res; 1997 Jun; 57(11):2140-3. PubMed ID: 9187111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia.
    Biankin AV; Kench JG; Morey AL; Lee CS; Biankin SA; Head DR; Hugh TB; Henshall SM; Sutherland RL
    Cancer Res; 2001 Dec; 61(24):8830-7. PubMed ID: 11751405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases.
    Costentin L; Pagès P; Bouisson M; Berthelémy P; Buscail L; Escourrou J; Pradayrol L; Vaysse N
    Pancreatology; 2002; 2(1):17-25. PubMed ID: 12120000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 and DPC4 alterations in the bile of patients with pancreatic carcinoma.
    Pantalone D; Pelo E; Minuti B; Giotti I; Mazza E; Falchini M; Neri B; Nesi G; Roberta Girardi L; Pulli R; Credi G; Torricelli F
    J Surg Oncol; 2004 Dec; 88(4):210-6. PubMed ID: 15565642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.